Tempus AI leverages artificial intelligence and data analytics to transform precision medicine. Its platforms integrate molecular and clinical data, empowering physicians to deliver personalized care across oncology, cardiology, neuropsychiatry, infectious diseases, and radiology, driving smarter, data-driven decisions across the healthcare landscape.
Tempus AI is redefining how cancer is understood and treated by blending artificial intelligence with the world’s most extensive clinical and molecular data library. Its powerful platform goes beyond standard diagnostics sequencing, both tumor and healthy cells, to uncover the hidden genetic drivers of each patient’s cancer. This allows physicians to move from one-size-fits-all treatments to personalized care strategies designed for better outcomes.
Its intelligent analytics engine then connects these genetic insights to targeted therapies and uniquely matched clinical trials. By turning complex data into clear, actionable guidance, Tempus empowers doctors to make faster, smarter decisions and gives patients a more hopeful path forward through precision medicine.
| Legal Name | Tempus AI, Inc |
| Headquarters | Chicago, Illinois, United States |
| Business Model | B2B, B2C |
| Founding Date | August 2015 |
| No. of Employees | Approx. 2,401 (As of 2025) |
| Eric Lefkofsky | Founder & Chief Executive Officer |
| Peter J. Barris | Board Director |
| Eric D. Belcher | Board Director |
| Jennifer A. Doudna, Ph.D. | Board Director |
| David R. Epstein | Board Director |
| Wayne A.I. Frederick, M.D. | Board Director |
| Scott Gottlieb, M.D. | Board Director |
| Theodore J. Leonsis | Board Director |
| Nadja West, M.D. | Board Director |
Tempus AI earns revenue through genomic sequencing, data licensing, AI-driven insights, and clinical trial support services. Its core stream, the Insights segment, provides licensed access to its de-identified molecular and clinical datasets. Additional revenue comes from partnerships with healthcare providers, pharmaceutical companies, and research institutions. A growing B2C stream also includes the Olivia app, offering personalized health data insights directly to consumers.
Client Segments: Primarily healthcare providers, pharmaceutical companies, biotech firms, research institutions, and some academic organizations.
Target Companies: Hospitals, Health Systems, Biopharma Companies, Research Labs, and Life Sciences Enterprises.
Target Geography: Global, including North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Client Segments: Individual patients, health-conscious consumers, individuals managing chronic conditions, and tech-savvy users seeking personalized health insights.
Target Users: Patients, Health App Users, Wellness Enthusiasts, Digital Health Consumers, and Early Adopters.
Target Geography: United States (initial launch), with planned future expansion to other global markets.